Generic Multaq Availability

Multaq is a brand name of dronedarone, approved by the FDA in the following formulation(s):

MULTAQ (dronedarone hydrochloride - tablet;oral)

Has a generic version of Multaq been approved?

No. There is currently no therapeutically equivalent version of Multaq available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Multaq. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Alkylaminoalkyl derivatives of benzofuran, benzothiophene, indole and indolizine, process for their preparation and compositions containing them
    Patent 5,223,510
    Issued: June 29, 1993
    Inventor(s): Gubin; Jean & Chatelain; Pierre & Lucchetti; Jean & Rosseels; Gilbert & Inion; Henri
    Assignee(s): Sanofi
    The subject of the invention is benzofuran, benzothiophene, indole or indolizine compounds of general formula: ##STR1## in which: Het represents one of the groups: ##STR2## in which T,T' and T"represent particularly a group: ##STR3## R and R.sub.a, identical or different, represent X represent --O-- or --S-- Y represents a radical ##STR4## These compounds are useful as medecines particularly for the treatment of pathological syndroms of the cardio-vascular system.
    Patent expiration dates:
    • July 26, 2016
      ✓ 
      Patent use: REDUCTION OF THE RISK OF HOSPITALIZATION FOR ATRIAL FIBRILLATION
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • July 26, 2016
      ✓ 
      Patent use: REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Solid pharmaceutical composition containing benzofuran derivatives
    Patent 7,323,493
    Issued: January 29, 2008
    Inventor(s): Abramovici; Bernard & Gautier; Jean-Claude & Gromenil; Jean-Claude & Marrier; Jean-Marie
    Assignee(s): Sanofi-Aventis
    The present invention relates to a solid pharmaceutical composition for oral administration characterized in that it comprises a benzofuran derivative with antiarrhythmic activity, or one of the pharmaceutically acceptable salts thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients.
    Patent expiration dates:
    • June 19, 2018
      ✓ 
      Drug product
  • Solid pharmaceutical compositions containing benzofuran derivatives
    Patent 8,318,800
    Issued: November 27, 2012
    Inventor(s): Abramovici; Bernard & Gautier; Jean-Claude & Gromenil; Jean-Claude & Marrier; Jean-Marie
    Assignee(s): Sanofi
    The present invention relates to a solid pharmaceutical composition for oral administration characterized in that it comprises a benzofuran derivative with antiarrhythmic activity, or one of the pharmaceutically acceptable salts thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients.
    Patent expiration dates:
    • June 19, 2018
      ✓ 
      Drug product
  • Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
    Patent 8,410,167
    Issued: April 2, 2013
    Assignee(s): SANOFI
    Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto.
    Patent expiration dates:
    • April 16, 2029
      ✓ 
      Patent use: TREATMENT OF PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS
    • April 16, 2029
      ✓ 
      Patent use: REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAILY WITH MORNING AND EVENING MEALS
  • Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
    Patent 8,602,215
    Issued: December 10, 2013
    Assignee(s): Sanofi
    The disclosure relates to a method for managing the risk of dronedarone/beta-blockers interaction by using dronedarone or pharmaceutically acceptable salts thereof in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors, who are in sinus rhythm or who will be cardioverted to reduce the risk of cardiovascular hospitalization, said patients also expecting to receive a beta-blockers treatment, by performing the following steps: a—initiate beta-blockers treatment at a low dose; b—performing a electrocardiogram (ECG) verification of good tolerability; c—increase of beta-blockers dose only if results in step b) are satisfying.
    Patent expiration dates:
    • June 30, 2031
      ✓ 
      Patent use: MANAGEMENT OF RISK OF DRONEDARONE/BETA-BLOCKER INTERACTION IN PATIENTS IN SINUS RYTHM WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • July 1, 2014 -

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web3)